|1.||Scrogin, Karie E: 3 articles (02/2007 - 06/2004)|
|2.||Gu, Baojun: 2 articles (01/2012 - 04/2007)|
|3.||Samini, Morteza: 2 articles (01/2012 - 03/2010)|
|4.||Hiegel, Cindy: 2 articles (07/2010 - 06/2003)|
|5.||Guptarak, Jutatip: 2 articles (07/2010 - 06/2003)|
|6.||Uphouse, Lynda: 2 articles (07/2010 - 06/2003)|
|7.||Wolf, William A: 2 articles (05/2007 - 05/2005)|
|8.||Osei-Owusu, Patrick: 2 articles (02/2007 - 06/2004)|
|9.||Tiniakov, Ruslan: 2 articles (02/2007 - 11/2006)|
|10.||Garcia-Cairasco, N: 1 article (10/2015)|
09/01/2002 - "8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produces a hypothermia in mice that serves as an in-vivo model of somatodendritic 5-HT1A autoreceptor function. "
01/01/1993 - "In contrast, the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) induced forepaw treading, flat body posture, hypothermia and hyperactivity which were not significantly different in aged compared to mature rats. "
01/01/1986 - "The tetralin derivative differs from apomorphine in that the first phase of hypermotility it induces is greater, and that hypothermia disappears at high doses."
01/01/1991 - "Subcutaneous injection of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in mice caused hypothermia which was antagonized by pindolol. "
02/01/1999 - "This study investigated the effect of markedly reducing corticosterone levels by ADX on 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)-induced hypothermia in mice, an in vivo model of somatodendritic 5-HT1A receptor function. "
05/01/1987 - "The administration of the putative 5-hydroxytryptamine1 (5-HT1) agonist 8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT) (0.0625-1.0 mg X kg-1) suppresses lordosis behaviour induced in ovariectomized female rats by daily treatment for 3-5 days with estradiol benzoate (1.25 micrograms/rat). "
02/01/2001 - "Previous studies showed that repeated estrogen treatment reduces the ability of the 5-HT(1A) receptor agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT), to inhibit lordosis behavior of female rats. "
07/01/2010 - "In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied. "
06/01/1999 - "The effects of bilateral VMN infusion with the 5-HT1A receptor agonist, (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 200, 1000, or 2000 ng), on lordosis behavior were examined in hormonally primed ovariectomized rats. "
06/01/1996 - "The effects of repeated treatment with estradiol benzoate to ovariectomized rats on the lordosis-inhibiting action of the 5-HT1A agonist, 8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT), were examined. "
|3.||Body Weight (Weight, Body)
03/01/2002 - "The role of 5-HT1A receptors in nutrient intake was also examined in a dose-response study (100-700 microg/kg body weight) of 8-hydroxy-2-(di-n-propylamino) tetralin (DPAT) in an acute restraint model. "
10/01/2014 - "To characterize the role of the 5-HT1A receptor (5-HT1A-R) in these eating disorders in females, we investigated the effect of saline or 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) treatment on feeding behavior and body weight in adult WT female mice and in adult 5-HT1A-R knockout (KO) female mice. "
07/01/2001 - "The effects of the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) and the DA D2/3 receptor agonist 7-OH-DPAT on core temperature was monitored in adult male Wistar rats, approximately 300 g body weight. "
|4.||Schizophrenia (Dementia Praecox)
01/01/1991 - "Binding studies with [3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT), a specific serotonin1A (5-HT1A) receptor agonist, were done on the autopsied brains from control subjects and from patients with chronic schizophrenia. "
06/01/1993 - "Serotonin (5-HT) uptake sites were mapped by autoradiographic means with [3H]cyano-imipramine ([3H]CN-IMI), the 5-HT1A receptor with [3H]8-hydroxy-2-[di-n-propyl-amino]tetralin ([3H]8-OH-DPAT), and the 5-HT2 receptor with both [3H]ketanserin and [125I]lysergic acid diethylamide ([125I]LSD) in eight nonneurologic controls and 10 cases with a diagnosis of schizophrenia. "
04/01/1998 - "The present studies were designed to characterize: (1) the requirement of the 5-HT1A receptor agonist R(+)-8-hydroxy-2-(di-n-propylamino) tetralin [R(+)8-OH-DPAT]-induced tachycardia on the integrity of serotonergic innervation of the preoptic area, (2) the ability of the 5-HT1A receptor partial agonist buspirone to elicit cardiovascular responses when microinjected into the preoptic area, (3) the role of 5-HT2 and 5-HT3 receptors in the preoptic area in cardiovascular regulation, and (4) the site specificity of the tachycardia produced by R(+)8-OH-DPAT. "
|1.||5-HT1A Serotonin Receptor
|3.||Serotonin (5 Hydroxytryptamine)
|4.||Serotonin 5-HT1 Receptor Agonists
|1.||East Asian Traditional Medicine (Oriental Medicine)